{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Sanjaisharma.jpg|frameless|upright=0.3|center]]
|<big>[[User:Sanjaisharma|Sanjai Sharma, MD]]<br>Visalia, CA</big>
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==EMN==
*'''2018:''' Gavriatopoulou et al. [https://www.nature.com/articles/s41375-018-0209-7 European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias] [https://www.ncbi.nlm.nih.gov/pubmed/30038381 PubMed]

==ESMO==
*'''2018:''' Kastritis et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Waldenstrom-s-Macroglobulinaemia Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
===Older===
*'''2013:''' Buske et al. [https://academic.oup.com/annonc/article/24/suppl_6/vi155/160941 Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]

==IWWM==
====Current====
*'''2016:''' Leblond et al. [http://www.bloodjournal.org/content/128/10/1321.long Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia]
====Older====
*'''2014:''' Dimopoulos et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148763/ Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus] [https://www.ncbi.nlm.nih.gov/pubmed/25027391 PubMed]
*'''2009:''' Dimopoulos et al. [http://jco.ascopubs.org/content/27/1/120.long Update on treatment recommendations from the Fourth International Workshop on Waldenström's Macroglobulinemia] [https://www.ncbi.nlm.nih.gov/pubmed/19047284 PubMed]
*'''2006:''' Treon et al. [http://www.bloodjournal.org/content/107/9/3442.long Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia] [https://www.ncbi.nlm.nih.gov/pubmed/16410453 PubMed]

==[https://www.nccn.org/ NCCN]==
[https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf NCCN Guidelines - Waldenström's Macroglobulinemia / Lymphoplasmacytic Lymphoma]

=First-line therapy, randomized data=

==BR {{#subobject:605f92|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab

===Regimen {{#subobject:82a333|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://ash.confex.com/ash/2012/webprogram/Paper48052.html Rummel et al. 2012 (StiL NHL 7-2008 (MAINTAIN)]
|style="background-color:#91cf61"|Non-randomized
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961763-2/fulltext Rummel et al. 2013 (StiL NHL1)]
|style="background-color:#91cf61"|Phase III, <20 pts in this subgroup (E)
|[[#R-CHOP|R-CHOP]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Note: efficacy for '''StiL NHL1''' is for the overall group of patients, of which less than 20 were diagnosed with WM.''
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications==== 
*Antiemetics, antipyretics, and antibiotics according to local standard of care
*Prophylactic use of [[:Category:Granulocyte colony-stimulating factors|G-CSF]] allowed according [http://jop.ascopubs.org/content/2/4/196.full ASCO guidelines] (2006)

'''28-day cycle for 6 cycles; StiL NHL1 gave 2 additional cycles of rituximab only'''
====Subsequent treatment====
*MAINTAIN: Observation versus rituximab maintenance

===References===
<!-- # Mathias J. Rummel, Norbert Niederle, Georg Maschmeyer, Andre G. Banat, Ulrich von Gruenhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz A. Duerk, Harald Ballo, Martina Stauch, Juergen Barth, Axel Hinke, Wolfram Brugger, Study Group Indolent Lymphomas (StiL). Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. 2012 ASCO Annual Meeting abstract 3. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview==abst_detail_view&confID==114&abstractID==95807 link to abstract] [http://www.ascopost.com/issues/july-1-2012/german-study-finds-bendamustine-improves-progression-free-survival-in-patients-with-non-hodgkin-lymphoma.aspx ASCO Post article] [http://www.asco.org/ASCOv2/MultiMedia/Virtual%20Meeting?&vmview==vm_session_presentations_view&confID==114&sessionID==4807 ASCO plenary session video] -->
# '''Abstract:''' Rummel, Mathias J., Lerchenmuller, Christian, Greil, Richard, Gorner, Martin, Hensel, Manfred, Engel, Erik, Jaeger, Ulrich, Breuer, Friedhelm, Hertenstein, Bernd, Prummer, Otto, Buske, Christian, Barth, Juergen, Burchardt, Alexander C., Brugger, Wolfram. Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7-2008 -MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214). ASH Annual Meeting Abstracts 2012 120: 2739 [https://ash.confex.com/ash/2012/webprogram/Paper48052.html link to abstract]
# '''StiL NHL1:''' Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; on behalf of the Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10. Epub 2013 Feb 20. Erratum in: Lancet. 2013 Apr 6;381(9873):1184. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961763-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23433739 PubMed]
## '''Update: Abstract:''' Mathias J. Rummel, MD, Georg Maschmeyer, MD, Arnold Ganser, Andrea Heider, PhD, Ulrich von Grünhagen, MD, PhD5, Christoph Losem, Gerhard Heil, MD, Manfred Welslau, Christina Balser, MD, Ulrich Kaiser, MD, Eckhart Weidmann, Heinz Dürk, MD, Hans Peter Böck, Martina Beate Stauch, MD, Jürgen Barth, Wolfgang Blau, MD, Alexander Burchardt, MD, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL)  7 Year Updated Results from the StiL NHL1 Study. ASH Annual Meeting 2014, Abstract 4407 [https://ash.confex.com/ash/2014/webprogram/Paper69997.html link to abstract]

==Chlorambucil monotherapy {{#subobject:2e7a3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:de904c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/3/301.full Leblond et al. 2012 (WM1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Fludarabine_monotherapy|Fludarabine]]
|style="background-color:#d73027"|Inferior OS
|-
|}
''This regimen was intended for patients greater than or equal to 18 years old with previously untreated WM and an [[Performance_status#ECOG_performance_status_.28WHO.2FZubrod_score.29|Eastern Cooperative Oncology Group (ECOG) performance status]] score less than or equal to 2.''
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] as follows:
**Age less than or equal to 75 years: 8 mg/m<sup>2</sup> PO once per day on days 1 to 10
**Age greater than 75 years: 6 mg/m<sup>2</sup> PO once per day on days 1 to 10

====Supportive medications====
*Recommended PCP prophylaxis with ONE of the following:
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim SS)]] 1 tablet PO once per day
**[[Pentamidine (Nebupent)]] 300 mg inhaled once per month

'''28-day cycle for up to 12 cycles'''

===References===
# Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. [http://jco.ascopubs.org/content/31/3/301.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23233721 PubMed]

==Fludarabine monotherapy {{#subobject:8df670|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:335f1b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/3/301.full Leblond et al. 2012 (WM1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Chlorambucil_monotherapy|Chlorambucil]]
|style="background-color:#1a9850"|Superior OS
|-
|}
''This regimen was intended for patients greater than or equal to 18 years old with previously untreated WM and an [[Performance_status#ECOG_performance_status_.28WHO.2FZubrod_score.29|Eastern Cooperative Oncology Group (ECOG) performance status]] score less than or equal to 2.''
====Chemotherapy====
*[[Fludarabine (Fludara)]] as follows:
**Age less than or equal to 75 years: 40 mg/m<sup>2</sup> PO once per day on days 1 to 5
**Age greater than 75 years: 30 mg/m<sup>2</sup> PO once per day on days 1 to 5

====Supportive medications====
*Recommended PCP prophylaxis with ONE of the following:
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim SS)]] 1 tablet PO once per day 
**[[Pentamidine (Nebupent)]] 300 mg inhaled once per month
*Varicella zoster (shingles) prophylaxis with ONE of the following:
**[[Valacyclovir (Valtrex)]] 500 mg PO once per day 
**[[Acyclovir (Zovirax)]] 200 to 400 mg PO twice per day 

'''28-day cycle for up to 6 cycles'''

===References===
# Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. [http://jco.ascopubs.org/content/31/3/301.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23233721 PubMed]

==Ibrutinib & Rituximab {{#subobject:cd5899|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9c9dee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1802917 Dimopoulos et al. 2018 (iNNOVATE)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Rituximab_monotherapy|Rituximab]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day
*[[Rituximab (Rituxan)]] as follows:
**Weeks 1 to 4: 375 mg/m<sup>2</sup> IV once per week for four weeks
**Weeks 17 to 20: 375 mg/m<sup>2</sup> IV once per week for four weeks

'''Continued indefinitely'''

===References===
# '''iNNOVATE:''' Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399-2410. Epub 2018 Jun 1. [https://www.nejm.org/doi/10.1056/NEJMoa1802917 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29856685 PubMed]

==Rituximab monotherapy {{#subobject:067613|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, single course (4 doses) {{#subobject:ee6861|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.1080/10428190410001714043 Gertz et al. 2004 (ECOG E3A98)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''4-week course'''

===Variant #2, "extended" course (8 doses) {{#subobject:a0f110|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/9/2327.long Dimopoulos et al. 2002]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.sciencedirect.com/science/article/pii/S1526965511702676 Dimopoulos et al. 2002]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://annonc.oxfordjournals.org/content/16/1/132.long Treon et al. 2005 (WMCTG)]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1802917 Dimopoulos et al. 2018 (iNNOVATE)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Ibrutinib_.26_Rituximab|Ibrutinib & Rituximab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Weeks 1 to 4: 375 mg/m<sup>2</sup> IV once per week for four weeks
**Weeks 12 to 15 (WMCTG) or 17 to 20 (iNNOVATE): 375 mg/m<sup>2</sup> IV once per week for four weeks

'''One course (8 doses total)'''

===References===
# Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol. 2002 May 1;20(9):2327-33. [http://jco.ascopubs.org/content/20/9/2327.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11981004 PubMed]
# Dimopoulos MA, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, Panayiotidis P, Vervessou E, Anagnostopoulos N, Christakis J. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma. 2002 Dec;3(3):163-6. [https://www.sciencedirect.com/science/article/pii/S1526965511702676 link to SD article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12521393 PubMed]
# '''ECOG E3A98:''' Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004 Oct;45(10):2047-55. [https://www.tandfonline.com/doi/full/10.1080/10428190410001714043 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15370249 PubMed]
# '''WMCTG:''' Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR; Waldenström's Macroglobulinemia Clinical Trials Group. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005 Jan;16(1):132-8. [http://annonc.oxfordjournals.org/content/16/1/132.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15598950 PubMed]
# '''iNNOVATE:''' Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399-2410. Epub 2018 Jun 1. [https://www.nejm.org/doi/10.1056/NEJMoa1802917 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29856685 PubMed]

==R-CHOP {{#subobject:d57eff|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CHOP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone
<br>R-CHOP-21
<br>CHOP-R
===Regimen {{#subobject:477737|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961763-2/fulltext Rummel et al. 2013 (StiL NHL1)]
|style="background-color:#91cf61"|Phase III, <20 pts in this subgroup (C)
|[[#BR|BR]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
''Note: efficacy for '''StiL NHL1''' is for the overall group of patients, of which <20 were diagnosed with WM.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''21-day cycle for up to maximum of 6 cycles'''

===Variant #2 {{#subobject:a3ac6d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nature.com/leu/journal/v23/n1/full/leu2008261a.html Buske et al. 2009]
|style="background-color:#1a9851"|Phase III (E)
|CHOP
|style="background-color:#1a9850"|Superior TTF
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day -1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for 4 to 8 cycles'''

===References===
# Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009 Jan;23(1):153-61. Epub 2008 Sep 25. [https://www.nature.com/leu/journal/v23/n1/full/leu2008261a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18818699 PubMed]
# '''StiL NHL1:''' Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; on behalf of the Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10. Epub 2013 Feb 20. Erratum in: Lancet. 2013 Apr 6;381(9873):1184. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961763-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23433739 PubMed]
## '''Update: Abstract:''' Mathias J. Rummel, MD, Georg Maschmeyer, MD, Arnold Ganser, Andrea Heider, PhD, Ulrich von Grünhagen, MD, PhD5, Christoph Losem, Gerhard Heil, MD, Manfred Welslau, Christina Balser, MD, Ulrich Kaiser, MD, Eckhart Weidmann, Heinz Dürk, MD, Hans Peter Böck, Martina Beate Stauch, MD, Jürgen Barth, Wolfgang Blau, MD, Alexander Burchardt, MD, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL)  7 Year Updated Results from the StiL NHL1 Study. ASH Annual Meeting 2014, Abstract 4407 [https://ash.confex.com/ash/2014/webprogram/Paper69997.html link to abstract]

=First-line therapy, non-randomized or retrospective data=

==BDR {{#subobject:2529c7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BDR: '''<u>B</u>'''ortezomib, '''<u>D</u>'''examethasone, '''<u>R</u>'''ituximab

===Variant #1 {{#subobject:5bb48a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727288/ Treon et al. 2009 (WMCTG 05-180)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: some details are missing in Treon et al. 2009; the updated abstract provides these additional details.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 40 mg IV once per day on days 1, 4, 8, 11
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 11

====Supportive medications====
*Varicella zoster (shingles) prophylaxis with ONE of the following recommended:
**[[Valacyclovir (Valtrex)]] 1 g PO once per day
**[[Acyclovir (Zovirax)]] 400 mg PO twice per day
*"The use of diphenhydramine, acetaminophen and, at the treating physician's discretion, corticosteroids and/or ranitidine or cimetidine was permitted for rituximab infusion prophylaxis. Granulocyte colony-stimulating factor, erythropoietin, and transfusions of packed RBCs or platelets were permitted to support patient's counts during therapy."
*"The prophylactic use of plasmapheresis was recommended for patients demonstrating an IgM level of greater than or equal to 5000 mg/dL before the administration of [[Rituximab (Rituxan)]], given the potential for rituximab-mediated IgM flare and aggravation of hyperviscosity."

'''21-day cycle for 4 cycles, followed by a 12-week pause and then 4 additional 21-day cycles spaced 12 weeks apart''' 

===Variant #2 {{#subobject:c745ca|Variant=1}}=== 
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://bloodjournal.hematologylibrary.org/content/122/19/3276.full Dimopoulos et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
''The schedule for this regimen can be confusing, in particular the first cycle is 21 days and the remaining cycles are 35 days.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] as follows:
**Cycle 1: 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
**Cycles 2 to 5: 1.6 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 2 and 5 only: 40 mg IV once per day on days 1, 8, 15, 22
*[[Rituximab (Rituxan)]] as follows:
**Cycles 2 and 5 only: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg PO once prior to [[Rituximab (Rituxan)]] infusions
*[[Diphenhydramine (Benadryl)]] 50 mg IV once prior to [[Rituximab (Rituxan)]] infusions
*Varicella zoster (shingles) prophylaxis with ONE of the following mandated:
**[[Valacyclovir (Valtrex)]] (dose not specified)
**[[Acyclovir (Zovirax)]] (dose not specified)

'''35-day cycle for 5 cycles (Cycle 1 is a 21-day cycle)'''

===References===
# Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J 2nd, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009 Aug 10;27(23):3830-5. Epub 2009 Jun 8. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727288/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19506160 PubMed] content property of [http://hemonc.org HemOnc.org]
## '''Update: Abstract:''' Steven P Treon, Kirsten Meid, Joshua Gustine, Christopher J Patterson, Jeffrey V. Matous, Irene M. Ghobrial, Jorge J Castillo. Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia. Blood 2015 126:1833. '''contains protocol''' [http://www.bloodjournal.org/content/126/23/1833 link to abstract] 
# Dimopoulos MA, García-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Kastritis E, Sonneveld P. Primary therapy of Waldenstrom's macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone and rituximab (BDR): long term results of a phase II study of the European Myeloma Network (EMN). Blood. 2013 Nov 7;122(19):3276-82. Epub 2013 Sep 4. [http://bloodjournal.hematologylibrary.org/content/122/19/3276.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24004667 PubMed]
## '''Update:''' Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Sonneveld P, Dimopoulos MA. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017 Jan 26;129(4):456-459. [http://www.bloodjournal.org/content/129/4/456.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27872060 PubMed]

==CaRD {{#subobject:af9cf2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CaRD: '''<u>Ca</u>'''rfilzomib, '''<u>R</u>'''ituximab, '''<u>D</u>'''examethasone

===Regimen {{#subobject:c4c704|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/124/4/503.long Treon et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV over 20 minutes once per day on days 1, 2, 8, 9 
**Subsequent cycles: 36 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 2, 8, 9
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 2 & 9, '''given third'''
*[[Dexamethasone (Decadron)]] 20 mg IV once per day on days 1, 2, 8, 9

====Supportive medications====
*[[Acyclovir (Zovirax)]] 400 mg PO twice per day for duration of therapy and continue for 6 months
*[[Famotidine (Pepcid)]] 20 mg PO twice per day during active therapy
*[[Dexamethasone (Decadron)]] 10 mg PO the night before [[Rituximab (Rituxan)]] was recommended
*Prophylactic plasmapheresis and hold on rituximab was recommended for patients demonstrating an IgM level of greater than or equal to 4000 mg/dL

'''21-day cycle for 6 cycles'''

''Patients with stable disease or better began [[#CaRD_2|CaRD maintenance]] 8 weeks later.''

===References===
<!-- Pre-publication not disclosed -->
# Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, Xu L, Cao Y, Yang G, Liu X, Patterson CJ, Warren D, Hunter ZR, Turnbull B, Ghobrial IM, Castillo JJ. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014 Jul 24;124(4):503-10. Epub 2014 May 23. [http://www.bloodjournal.org/content/124/4/503.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24859363 PubMed]

==Cladribine & Rituximab {{#subobject:487557|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:480162|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/13/2233.long Laszlo et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 0.1 mg/kg SC once per day on days 1 to 5
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''Monthly cycle for 4 cycles'''

===References===
# Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol. 2010 May 1;28(13):2233-8. Epub 2010 Apr 5. [http://jco.ascopubs.org/content/28/13/2233.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20368573 PubMed] 

==DRC {{#subobject:586f5f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DRC: '''<u>D</u>'''examethasone, '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide 

===Regimen {{#subobject:225310|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/25/22/3344.long Dimopoulos et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}

''Note: The body text of Dimopoulos et al 2007 said that the regimen is given for "six courses," whereas the abstract says that it is given for 6 months."''
====Chemotherapy====
*[[Dexamethasone (Decadron)]] 20 mg IV once on day 1, '''given first'''
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1, '''given second'''
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO twice per day on days 1 to 5 (total dose per cycle: 1000 mg/m<sup>2</sup>) 

'''21-day cycle for 6 cycles'''

===References===
# Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A, Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007 Aug 1;25(22):3344-9. [http://jco.ascopubs.org/content/25/22/3344.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17577016 PubMed]
## '''Update:''' '''Abstract:''' Dimopoulos, Meletios A., Roussou, Maria, Kastritis, Efstathios, Hadjiharissi, Evdoxia, Kyrtsonis, Marie-Christine, Symeonidis, Argiris, Repoussis, Panagiotis, Michalis, Eurydiki, Delimpasi, Sosana, Tsatalas, Konstantinos, Tsirigotis, Panagiotis, Vassou, Amalia, Vervessou, Elina, Katodritou, Eirini, Gavriatopoulou, Maria, Gika, Dimitra, Terpos, Evangelos, Zervas, Konstantinos. Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study. ASH Annual Meeting Abstracts 2012 120: 438 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/438 link to abstract]
## '''Update:''' Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood. 2015 Sep 10;126(11):1392-4. [http://www.bloodjournal.org/content/126/11/1392.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26359434 PubMed]

==Everolimus monotherapy {{#subobject:f542c8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:ce8c8f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://clincancerres.aacrjournals.org/content/23/10/2400.long Treon et al. 2016 (WMCTG 09-214)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Everolimus (Afinitor)]] 10 mg PO once per day

'''28-day cycles'''

===References===
<!-- # '''Abstract:''' Treon, Steven P, Tripsas, Christina K, Ioakimidis, Leukothea, Warren, Diane, Patterson, Christopher, Heffner, Leonard, Eradat, Herbert, Gregory, Stephanie A., Thomas, Sheeba, Advani, Ranjana, Baz, Rachid, Badros, Ashraf Z., Matous, Jeffrey, Anderson, Kenneth C., Ghobrial, Irene M. Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. ASH Annual Meeting Abstracts 2011 118: 2951 [http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/2951 link to abstract]
## '''Update:''' '''Abstract:''' Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, Kirsten Meid, Christopher Patterson, Leonard T Heffner, Herbert Eradat, Stephanie A. Gregory, Sheeba K. Thomas, Ranjana H. Advani, Rachid Baz, Ashraf Z. Badros, Jeffrey Matous, Timothy J. Murphy, Irene M. Ghobrial. Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstroms Macroglobulinemia. Blood Nov 2013,122(21)1822 [http://www.bloodjournal.org/content/122/21/1822 link to abstract] -->
# '''WMCTG 09-214:''' Treon SP, Meid K, Tripsas C, Heffner LT, Eradat H, Badros AZ, Xu L, Hunter ZR, Yang G, Patterson CJ, Gustine J, Castillo JJ, Matous J, Ghobrial IM. Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15;23(10):2400-2404. Epub 2016 Nov 11. [http://clincancerres.aacrjournals.org/content/23/10/2400.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27836860 PubMed]

==FCR {{#subobject:a28be1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FCR: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''ituximab

===Regimen {{#subobject:95fab8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.26303/full Tedeschi et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV once per day on days 2 to 4
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV once per day on days 2 to 4
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] (dose not specified) IV prior to [[Rituximab (Rituxan)]] 
*[[Acetaminophen (Tylenol)]] (dose not specified) PO prior to [[Rituximab (Rituxan)]]
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] (dose not specified) PO three times per week during and for 6 months after treatment
*[[Acyclovir (Zovirax)]] 800 mg PO once per day during and for 6 months after treatment

'''28-day cycle for up to 6 cycles'''

===References===
# Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, Meneghini V, Pioltelli P, Sacchi S, Ricci F, Nichelatti M, Zaja F, Lazzarino M, Vitolo U, Morra E. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2012 Jan 15;118(2):434-43. Epub 2011 Jul 5. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.26303/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21732338 PubMed]

==Fludarabine monotherapy {{#subobject:8df670|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:3c512d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/98/1/41 Dhodapkar et al. 2001 (S9003)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''28-day cycle for 4 to 8 cycles'''

===References===
# Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001 Jul 1;98(1):41-8. [http://www.bloodjournal.org/content/98/1/41 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11418461 PubMed]
## '''Update:''' Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol. 2003 Apr;30(2):220-5. [https://www.ncbi.nlm.nih.gov/pubmed/12720140 PubMed] 
## '''Update:''' Dhodapkar MV, Hoering A, Gertz MA, Rivkin S, Szymonifka J, Crowley J, Barlogie B. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood. 2009 Jan 22;113(4):793-6. Epub 2008 Oct 17. [http://www.bloodjournal.org/content/113/4/793.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630265/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18931340 PubMed]

==FR {{#subobject:49db19|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FR: '''<u>F</u>'''ludarabine & '''<u>R</u>'''ituximab
===Regimen {{#subobject:d29208|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670786/ Treon et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] as follows:
**Weeks 5, 9, 13, 19, 23, 27: 25 mg/m<sup>2</sup> (route not specified) once per day on days 1 to 5
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week on weeks 1 to 4, 17, 18, 30, 31 (8 doses total)

'''One course'''

===References===
# Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009 Apr 16;113(16):3673-8. Epub 2008 Nov 17. [http://www.bloodjournal.org/content/113/16/3673.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670786/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19015393 PubMed]

==Ibrutinib monotherapy {{#subobject:26f7d8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a0b905|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.78.6426 Treon et al. 2018 (DFCI 15-359)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day

'''Continued indefinitely'''

===References===
# '''DFCI 15-359:''' Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, Demos M, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Chan G, Dubeau T, Raje N, Yee A, O'Donnell E, Hunter ZR, Castillo JJ. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia. J Clin Oncol. 2018 Sep 20;36(27):2755-2761. Epub 2018 Jul 25. [http://ascopubs.org/doi/full/10.1200/JCO.2018.78.6426 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30044692 PubMed]

==Ofatumumab monotherapy {{#subobject:ed42ea|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:82d5c8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext Furman et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed.''
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] as follows (choose one):
**Option 1: 300 mg IV once on week 1 and 1000 mg IV once per week on weeks 2 to 4
**Option 2: 300 mg IV once on week 1 and 2000 mg IV once per week on weeks 2 to 5

'''4-week or 5-week course'''

===References===
<!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] -->
# Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27914971 PubMed]

==PCR {{#subobject:f0460f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PCR: '''<u>P</u>'''entostatin, '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''ituximab
<br>PER: '''<u>P</u>'''entostatin, '''<u>E</u>'''ndoxan (Cyclophosphamide), '''<u>R</u>'''ituximab
===Regimen {{#subobject:138964|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.tandfonline.com/doi/full/10.3109/10428194.2014.911869 Herth et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pentostatin (Nipent)]] 4 mg/m<sup>2</sup> IV once on day 2
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> (route not specified) on day 2
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
**Note: rituximab is not given in cycle 1 if WBC count greater than 50 x 10<sup>9</sup>/L

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*Patients with CR/PR: [[#Rituximab_monotherapy_2|Rituximab maintenance]]

===References===
# Herth I, Hensel M, Rieger M, Horstmann K, Hiddemann W, Dreyling M, Koniczek S, Witzens-Harig M, Ho AD. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia. Leuk Lymphoma. 2015 Jan;56(1):97-102. Epub 2014 Jun 25. [http://www.tandfonline.com/doi/full/10.3109/10428194.2014.911869 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24724778 PubMed]

==Thalidomide & Rituximab {{#subobject:5b5bcb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:6cf3cf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597120/ Treon et al. 2008 (DFCI 03-077)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Thalidomide (Thalomid)]] as follows:
**200 mg PO once per day x 2 weeks, then
**400 mg PO once per day x 50 weeks
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week on weeks 2 to 5 and weeks 13 to 16 (8 doses total)

'''52-week course'''

===References===
# '''DFCI 03-077:''' Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Briccetti FM, Pasmantier M, Zimbler H, Cooper RB, Moore M, Hill J 2nd, Rauch A, Garbo L, Chu L, Chua C, Nantel SH, Lovett DR, Boedeker H, Sonneborn H, Howard J, Musto P, Ciccarelli BT, Hatjiharissi E, Anderson KC. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008 Dec 1;112(12):4452-7. Epub 2008 Aug 19. [http://www.bloodjournal.org/content/112/12/4452.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597120/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18713945 PubMed]

==Thioguanine monotherapy {{#subobject:23f115|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5168bf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM196304042681403 Weiss et al. 1963]
| style="background-color:#ffffbe" |Pilot
|-
|}
''Of historic interest.''
====Chemotherapy====
*[[Thioguanine (Tabloid)]]
===References===
# Weiss CH, Demis DJ, Elgart ML, Brown CS, Crosby WH. Treatment of two cases of hyperglobulinemic purpura with thioguanine. N Engl J Med. 1963 Apr 4;268:753-6. [https://www.nejm.org/doi/full/10.1056/NEJM196304042681403 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/13999713 PubMed]

==VR {{#subobject:872f6d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VR: '''<u>V</u>'''elcade (Bortezomib) & '''<u>R</u>'''ituximab
===Regimen {{#subobject:322519|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/ajh.21788/full Ghobrial et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.6 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Rituximab (Rituxan)]] as follows:
**Cycles 1 to 4: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

====Supportive medications====
*"Antiviral prophylaxis was recommended in all patients prior to initiation of therapy and for 3 months after completion of the six cycles."

'''28-day cycle for up to 6 cycles'''

===References===
# Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010 Sep;85(9):670-4. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.21788/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20652865 PubMed]
=Maintenance after first-line therapy=

==CaRD {{#subobject:d5202e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CaRD: '''<u>Ca</u>'''rfilzomib, '''<u>R</u>'''ituximab, '''<u>D</u>'''examethasone

===Regimen {{#subobject:05da75|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/124/4/503.long Treon et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#CaRD|CaRD induction]] x 6 cycles
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] 36 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 2, '''given third'''
*[[Dexamethasone (Decadron)]] 20 mg IV once per day on days 1 & 2

'''8-week cycle for 8 cycles'''

===References===
<!-- Pre-publication not disclosed -->
# Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, Xu L, Cao Y, Yang G, Liu X, Patterson CJ, Warren D, Hunter ZR, Turnbull B, Ghobrial IM, Castillo JJ. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014 Jul 24;124(4):503-10. Epub 2014 May 23. [http://www.bloodjournal.org/content/124/4/503.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24859363 PubMed]

==Rituximab monotherapy {{#subobject:9e5742|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:52250f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.tandfonline.com/doi/full/10.3109/10428194.2014.911869 Herth et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#PCR|PER]] x 6
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''3-month cycles for 2 years'''

===References===
# Herth I, Hensel M, Rieger M, Horstmann K, Hiddemann W, Dreyling M, Koniczek S, Witzens-Harig M, Ho AD. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia. Leuk Lymphoma. 2015 Jan;56(1):97-102. Epub 2014 Jun 25. [http://www.tandfonline.com/doi/full/10.3109/10428194.2014.911869 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24724778 PubMed]

=Relapsed or refractory, randomized data=

==BR {{#subobject:a69074|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab

===Regimen {{#subobject:6b3ab8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00447-7/fulltext Rummel et al. 2015 (StiL NHL 2-2003)]
|style="background-color:#1a9851"|Phase III (E)
|[[#FR_2|FR]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2 
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 6 cycles'''

===References===
<!-- # '''Abstract:''' Mathias J. Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke and Juergen Barth. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting 2010, Abstract 856 [https://ash.confex.com/ash/2010/webprogram/Paper26917.html link to abstract]
## '''Update:''' '''Abstract:''' Mathias J. Rummel, MD, Christina Balser, MD, Ulrich Kaiser, MD, Hans Peter Böck, Martina Beate Stauch, MD, Andrea Heider, PhD, Manfred Welslau, Christoph Losem, Eckhart Weidmann, Wolfgang Blau, MD, Alexander Burchardt, MD, Jürgen Barth, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting 2014, Abstract 145 [https://ash.confex.com/ash/2014/webprogram/Paper69154.html link to abstract] -->
# '''StiL NHL 2-2003:''' Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. Epub 2015 Dec 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00447-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26655425 PubMed]

==FR {{#subobject:f36d77|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FR: '''<u>F</u>'''ludarabine & '''<u>R</u>'''ituximab
===Regimen {{#subobject:aa26e7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00447-7/fulltext Rummel et al. 2015 (StiL NHL 2-2003)]
|style="background-color:#1a9851"|Phase III (C)
|[[#BR_2|BR]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> (route not specified) once per day on days 1 to 3
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 6 cycles'''

===References===
<!-- # '''Abstract:''' Mathias J. Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke and Juergen Barth. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting 2010, Abstract 856 [https://ash.confex.com/ash/2010/webprogram/Paper26917.html link to abstract]
## '''Update:''' '''Abstract:''' Mathias J. Rummel, MD, Christina Balser, MD, Ulrich Kaiser, MD, Hans Peter Böck, Martina Beate Stauch, MD, Andrea Heider, PhD, Manfred Welslau, Christoph Losem, Eckhart Weidmann, Wolfgang Blau, MD, Alexander Burchardt, MD, Jürgen Barth, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting 2014, Abstract 145 [https://ash.confex.com/ash/2014/webprogram/Paper69154.html link to abstract] -->
# '''StiL NHL 2-2003:''' Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. Epub 2015 Dec 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00447-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26655425 PubMed]

==Ibrutinib & Rituximab {{#subobject:952daf|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:62d700|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1802917 Dimopoulos et al. 2018 (iNNOVATE)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Rituximab_monotherapy_2|Rituximab]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day
*[[Rituximab (Rituxan)]] as follows:
**Weeks 1 to 4: 375 mg/m<sup>2</sup> IV once per week for four weeks
**Weeks 17 to 20: 375 mg/m<sup>2</sup> IV once per week for four weeks

'''Continued indefinitely'''

===References===
# '''iNNOVATE:''' Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399-2410. Epub 2018 Jun 1. [https://www.nejm.org/doi/10.1056/NEJMoa1802917 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29856685 PubMed]

==Rituximab monotherapy {{#subobject:426958|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, single course (4 doses) {{#subobject:1a66a9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.1080/10428190410001714043 Gertz et al. 2004 (ECOG E3A98)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''4-week course'''

===Variant #2, "extended" course (8 doses) {{#subobject:cd7fa0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/9/2327.long Dimopoulos et al. 2002]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://annonc.oxfordjournals.org/content/16/1/132.long Treon et al. 2005 (WMCTG)]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1802917 Dimopoulos et al. 2018 (iNNOVATE)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Ibrutinib_.26_Rituximab_2|Ibrutinib & Rituximab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Weeks 1 to 4: 375 mg/m<sup>2</sup> IV once per week for four weeks
**Weeks 12 to 15 (WMCTG) or 17 to 20 (iNNOVATE): 375 mg/m<sup>2</sup> IV once per week for four weeks

'''One course (8 doses total)'''

===References===
# Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol. 2002 May 1;20(9):2327-33. [http://jco.ascopubs.org/content/20/9/2327.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11981004 PubMed]
# '''ECOG E3A98:''' Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004 Oct;45(10):2047-55. [https://www.tandfonline.com/doi/full/10.1080/10428190410001714043 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15370249 PubMed]
# '''WMCTG:''' Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR; Waldenström's Macroglobulinemia Clinical Trials Group. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005 Jan;16(1):132-8. [http://annonc.oxfordjournals.org/content/16/1/132.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15598950 PubMed]
# '''iNNOVATE:''' Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399-2410. Epub 2018 Jun 1. [https://www.nejm.org/doi/10.1056/NEJMoa1802917 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29856685 PubMed]

=Relapsed or refractory, non-randomized or retrospective data=

==Alemtuzumab monotherapy {{#subobject:fcafbf|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9db0c8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138682/ Treon et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}

''Per the authors, "Alemtuzumab is an active therapy.., but short- and long-term toxicities need to be carefully weighed against other available treatment options."''
====Chemotherapy====
*[[Alemtuzumab (Campath)]] as follows:
** 3 test doses of 3 mg IV, 10 mg IV, and 30 mg IV over 1 week
** 30 mg IV three times per week x 12 weeks (36 doses)

====Supportive medications====
*1 L of normal saline prior to [[Alemtuzumab (Campath)]]
*[[Acetaminophen (Tylenol)]] 650 mg PO prior to [[Alemtuzumab (Campath)]]
*[[Diphenhydramine (Benadryl)]] 50 mg IV prior to [[Alemtuzumab (Campath)]]
*[[Hydrocortisone (Cortef)]] 100 to 200 mg IV prior to [[Alemtuzumab (Campath)]] if patient had a prior reaction
*[[Cimetidine (Tagamet)]] 300 mg IV prior to [[Alemtuzumab (Campath)]] if patient had a prior reaction
*[[Famciclovir (Famvir)]] 250 mg PO twice per day "or the equivalent" during treatment and for 3 months afterwards
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] PO twice per day three times per week during treatment and for 3 months afterwards
**[[Dapsone (Aczone)]] (dose not specified) instead, for patients with sulfur allergy

'''13-week treatment course'''

===References===
# Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011 Jul 14;118(2):276-81. Epub 2011 May 12. [http://www.bloodjournal.org/content/118/2/276.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138682/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21566092 PubMed]

==Allogeneic hematopoietic stem cell transplant==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/33/4926.long Kyriakou et al. 2010]
|style="background-color:#ffffbe"|Retrospective
|-
|}
''Retrospective series; included here for reference purposes only.''
===References===
# '''Retrospective:''' Kyriakou C, Canals C, Cornelissen JJ, Socié G, Willemze R, Ifrah N, Greinix HT, Blaise D, Deconinck E, Ferrant A, Schattenberg A, Harousseau JL, Sureda A, Schmitz N. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010 Nov 20;28(33):4926-34. Epub 2010 Oct 18. [http://jco.ascopubs.org/content/28/33/4926.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20956626 PubMed]

==Bortezomib monotherapy {{#subobject:b39c1b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 4 cycles {{#subobject:79eabf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.haematologica.org/content/90/12/1655.long Dimopoulos et al. 2005]
| style="background-color:#ffffbe" |Phase II, <20 pts
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11

'''21-day cycle for 4 cycles'''

===Variant #2, 8 cycles {{#subobject:033f4b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://clincancerres.aacrjournals.org/content/13/11/3320.long Treon et al. 2007 (WMCTG 03-248)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11

'''Up to 8 cycles (cycle duration not defined)'''

===Variant #3, response-adapted {{#subobject:e70734|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.07.8659 Chen et al. 2007 (WMCTG 03-248)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11

'''21-day cycles until PD or 2 cycles past CR or stable PR'''

===References===
# Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib. Haematologica. 2005 Dec;90(12):1655-8. [http://www.haematologica.org/content/90/12/1655.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16330439 PubMed]
<!-- Presented in part at the Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego, CA, and at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6 2006, Atlanta, GA. -->
# Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E; National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 Apr 20;25(12):1570-5. [http://ascopubs.org/doi/full/10.1200/JCO.2006.07.8659 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17353550 PubMed]
<!-- no reported pre-publication -->
# Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, Cook D, Songer J, Hill J, Kaden BR, Sharon D, Steiss R, Leleu X, Branagan AR, Badros A. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007 Jun 1;13(11):3320-5. [http://clincancerres.aacrjournals.org/content/13/11/3320.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17545538 PubMed]

==BR {{#subobject:f08e17|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab
===Variant #1, 4 cycles {{#subobject:de48ba|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/15/3383.long Rummel et al. 2005]
|style="background-color:#ffffbe"|Phase II, <20 pts in this subgroup
|-
|}
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 2 & 3
*[[Rituximab (Rituxan)]] as follows:
**One week prior to start of cycle 1: 375 mg/m<sup>2</sup> IV once
**Cycles 1 to 4: 375 mg/m<sup>2</sup> IV once on day 1
**4 weeks after cycle 4: 375 mg/m<sup>2</sup> IV once

'''28-day cycle for 4 cycles'''

===Variant #2, indefinite {{#subobject:8afb07|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(11)70151-3/fulltext Treon et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 OR day 2

'''28-day cycles'''

===References===
# Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005 May 20;23(15):3383-9. [http://jco.ascopubs.org/content/23/15/3383.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15908650 PubMed]
# Treon SP, Hanzis C, Tripsas C, Ioakimidis L, Patterson CJ, Manning RJ, Sheehy P. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):133-5. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(11)70151-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21454214 PubMed]

==Cladribine & Rituximab {{#subobject:4fcea7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:1802a1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/13/2233.long Laszlo et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 0.1 mg/kg SC once per day on days 1 to 5
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''Monthly cycle for 4 cycles'''

===References===
# Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol. 2010 May 1;28(13):2233-8. Epub 2010 Apr 5. [http://jco.ascopubs.org/content/28/13/2233.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20368573 PubMed] 

==Everolimus monotherapy {{#subobject:b2d1f4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f404b0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834498/ Ghobrial et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Everolimus (Afinitor)]] 10 mg PO once per day while fasting

====Supportive medications====
*[[:Category:Granulocyte_colony-stimulating_factors|WBC growth factors]] per physician discretion if neutropenia occurred, but it was not to be used prophylactically in order to maintain dosing.
*[[:Category:Erythrocyte_growth_factors|Erythropoietin]] for anemia allowed per physician discretion.

'''28-day cycles'''

===References===
<!-- no pre-publication disclosed -->
# Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10;28(8):1408-14. Epub 2010 Feb 8. [http://jco.ascopubs.org/content/28/8/1408.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834498/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20142598 PubMed]
## '''Update:''' Ghobrial IM, Witzig TE, Gertz M, LaPlant B, Hayman S, Camoriano J, Lacy M, Bergsagel PL, Chuma S, DeAngelo D, Treon SP. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014 Mar;89(3):237-42. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23620/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24716234 PubMed]

==FR {{#subobject:9598c5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FR: '''<u>F</u>'''ludarabine & '''<u>R</u>'''ituximab
===Regimen {{#subobject:acd701|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670786/ Treon et al. 2008]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] as follows:
**Weeks 5, 9, 13, 19, 23, 27: 25 mg/m<sup>2</sup> (route not specified) once per day on days 1 to 5
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week on weeks 1 to 4, 17, 18, 30, 31 (8 doses total)

'''One course'''

===References===
# Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009 Apr 16;113(16):3673-8. Epub 2008 Nov 17. [http://www.bloodjournal.org/content/113/16/3673.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670786/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19015393 PubMed]

==Ibrutinib monotherapy {{#subobject:e206e9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8f956b|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1501548 Treon et al. 2015 (DFCI 12-015)]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30632-5/fulltext Dimopoulos et al. 2016 (iNNOVATE substudy)]
|style="background-color:#91cf61"|Non-randomized
|-
|}
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day

'''Continued for up to 2 years'''

===References===
<!-- # '''Abstract:''' Treon SP, Tripsas CK, Yang G, et al: A prospective multicenter study of the Brutons tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstroms macroglobulinemia. 2013 ASH Annual Meeting abstract 251 [https://ash.confex.com/ash/2013/webprogram/Paper64876.html link to abstract] -->
# '''DFCI 12-015:''' Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr 9;372(15):1430-40. [https://www.nejm.org/doi/full/10.1056/NEJMoa1501548 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25853747 PubMed]
## '''Subgroup analysis:''' Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenström's macroglobulinemia. N Engl J Med. 2015 Aug 6;373(6):584-6. [https://www.nejm.org/doi/full/10.1056/NEJMc1506192 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26244327 PubMed]
# '''iNNOVATE substudy:''' Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb;18(2):241-250. Epub 2016 Dec 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30632-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27956157 PubMed]

==Idelalisib monotherapy {{#subobject:eb4fb0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
'''On 3/21/2016 Gilead announced that they were stopping seven clinical trials of idelalisib in patients with CLL, SLL, and iNHL due to excess deaths and increased rates of SAEs. A [http://www.zydeligrems.com/ REMS program] has also been announced.'''

===Regimen {{#subobject:696cb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039496/ Gopal et al. 2014 (DELTA)]
|style="background-color:#ffffbe"|Phase II, <20 pts in this subgroup
|-
|}
====Chemotherapy====
*[[Idelalisib (Zydelig)]] 150 mg PO twice per day

'''Continued indefinitely'''

===References===
# Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kd Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. N Engl J Med. 2014 Jan 22. [https://www.nejm.org/doi/full/10.1056/NEJMoa1314583 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039496/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24450858 PubMed]
## '''Update:''' '''Abstract:''' Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD, PhD, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, PhD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD and Gilles Andre Salles, MD, PhD. Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). ASH Annual Meeting 2014, Abstract 1708 [https://ash.confex.com/ash/2014/webprogram/Paper74940.html link to abstract]

==Lenalidomide monotherapy {{#subobject:5bd6bb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a1f080|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/ajh.24175/abstract Fouquet et al. 2015]
|style="background-color:#ffffbe"|Phase I/II, <20 pts
|-
|}
''This is the MTD determined in the phase I portion of the study.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 21

'''28-day cycles'''

===References===
# Fouquet G, Guidez S, Petillon MO, Louni C, Ohyba B, Dib M, Poulain S, Herbaux C, Martin A, Thielemans B, Brice P, Choquet S, Bakala J, Bories C, Demarquette H, Nudel M, Tournilhac O, Arnulf B, LeGouill S, Morel P, Banos A, Karlin L, Salles G, Leblond V, Leleu X. Lenalidomide is safe and active in Waldenström macroglobulinemia. Am J Hematol. 2015 Nov;90(11):1055-9. Epub 2015 Oct 6. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.24175/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26284823 PubMed]

==Ofatumumab monotherapy {{#subobject:940cf5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:3a7181|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext Furman et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed.''
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] as follows (choose one):
**Option 1: 300 mg IV once on week 1 and 1000 mg IV once per week on weeks 2 to 4
**Option 2: 300 mg IV once on week 1 and 2000 mg IV once per week on weeks 2 to 5

'''4-week or 5-week course'''

===References===
<!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] -->
# Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27914971 PubMed]

==Panobinostat monotherapy {{#subobject:f079ae|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:2221fe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578951/ Ghobrial et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Panobinostat (Farydak)]] 30 mg PO 3 days per week (Mondays, Wednesdays, and Fridays)

'''28-day cycles'''
	
===References===
# Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013 Feb 21;121(8):1296-303. Epub 2013 Jan 3. [http://bloodjournal.hematologylibrary.org/content/121/8/1296.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578951/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23287861 PubMed]

==RVR {{#subobject:d47682|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RVR: '''<u>R</u>'''AD-001 (Everolimus), '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''ituximab

===Regimen {{#subobject:cd69f4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/leu/journal/v29/n12/full/leu2015164a.html Ghobrial et al. 2015]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''These are the doses of the phase II portion of the study.''
====Chemotherapy====
*[[Everolimus (Afinitor)]] 10 mg PO once per day
*[[Bortezomib (Velcade)]] 1.6 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Rituximab (Rituxan)]] as follows:
**Cycles 1 & 4: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Everolimus_monotherapy_3|Everolimus maintenance]]

===References===
# Ghobrial IM, Redd R, Armand P, Banwait R, Boswell E, Chuma S, Huynh D, Sacco A, Roccaro AM, Perilla-Glen A, Noonan K, MacNabb M, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Weller E, Treon SP. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec;29(12):2338-46. Epub 2015 Jul 3. [https://www.nature.com/leu/journal/v29/n12/full/leu2015164a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26139427 PubMed]
==VR {{#subobject:a30c1b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VR: '''<u>V</u>'''elcade (Bortezomib) & '''<u>R</u>'''ituximab
===Regimen {{#subobject:f70744|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834499/ Ghobrial et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.6 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Rituximab (Rituxan)]] as follows:
**Cycles 1 to 4: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

====Supportive medications====
*"At the time of initiation of the study, the incidence of herpes zoster reactivation with bortezomib in WM was not well documented; therefore, antiviral prophylaxis was not mandated."

'''28-day cycle for up to 6 cycles'''

===References===
<!-- no reported pre-publication -->
# Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10;28(8):1422-8. Epub 2010 Feb 8. [http://jco.ascopubs.org/content/28/8/1422.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834499/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20142586 PubMed]
=Maintenance after subsequent lines of therapy=

==Everolimus monotherapy {{#subobject:a81ea4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b686db|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/articles/leu2015164 Ghobrial et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#RVR|RVR]] x 6
====Chemotherapy====
*[[Everolimus (Afinitor)]] 10 mg PO once per day

'''Continued indefinitely'''

===References===
# Ghobrial IM, Redd R, Armand P, Banwait R, Boswell E, Chuma S, Huynh D, Sacco A, Roccaro AM, Perilla-Glen A, Noonan K, MacNabb M, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Weller E, Treon SP. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec;29(12):2338-46. Epub 2015 Jul 3. [https://www.nature.com/articles/leu2015164 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26139427 PubMed]

=Response criteria=
==Current==
*'''2012:''' [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12102/full Response assessment in Waldenström macroglobulinaemia: Update from the VIth International Workshop]

==Older==
*'''2003:''' [https://www.ncbi.nlm.nih.gov/pubmed/12720121 Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia]

[[Category:Waldenström macroglobulinemia regimens]]
[[Category:Disease-specific pages]]
[[Category:Indolent lymphomas]]
